{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-23-000078","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.726657+00:00","generated_at":"2026-06-19T22:53:58.564358+00:00","sec_items":["5.03"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Regen Biopharma files 1-for-1500 reverse stock split and reduces preferred voting power","bullets":["Series AA preferred votes reduced to 7 per share; Series NC to 334 per share, effective March 6, 2023.","1-for-1500 reverse stock split authorized for all common and preferred stock, effective March 6, 2023.","Reverse split consolidates shares at a 1500:1 ratio, drastically reducing outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-23-000078","json":"https://secwatch.observer/filing/0001607062-23-000078.json","markdown":"https://secwatch.observer/filing/0001607062-23-000078.md","text":"https://secwatch.observer/filing/0001607062-23-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000078/0001607062-23-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000078/rgbp020623form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:53:58.564358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b4d9be49542c08903ca22872b9cfbbc930cdd49","claim":"Regen BioPharma Inc: Amendment to Certificate of Designations reducing Series AA Preferred Stock votes per share to seven as of March 6, 2023 (effective 2023-03-06).","evidence_excerpt":"An amendment to the Certificate of Designations of the Company’s Series AA Preferred Stock reducing that number of votes per share of Series AA Preferred stock to seven votes per share as of March 6, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000078/0001607062-23-000078-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-06"}],"fact_type":"governance_change"},{"claim_id":"afbe3d712973970a571f18a990a52fe4ebd9146d","claim":"Regen BioPharma Inc: Certificate of Change authorizing 1-for-1500 reverse stock split of all issued series of stock effective March 6, 2023 (effective 2023-03-06).","evidence_excerpt":"A Certificate of Change authorizing 1 for 1500 reverse stock split of all issued series of stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000078/0001607062-23-000078-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-06"}],"fact_type":"governance_change"},{"claim_id":"e35d5b465abb5158611a78b968a04c16038d7766","claim":"Regen BioPharma Inc: Amendment to Certificate of Designations reducing Series NC Preferred Stock votes per share to 334 as of March 6, 2023 (effective 2023-03-06).","evidence_excerpt":"An amendment to the Certificate of Designations of the Company’s Series NC Preferred Stock reducing that number of votes per share of Series NC Preferred stock to three hundred and thirty four votes per share as of March 6, 2023","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000078/0001607062-23-000078-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-03-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}